Testing technology

For identifying and detailed study of each individually obtained biomarker, Caris Life Sciences uses the multiplatform tumor profiling technology such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH), next-generation sequencing (NGS) and polymerase Chain Reaction (PCR).

In conjunction with a comprehensive review of researches, the results of these tests allow physicians to personalize treatment.

  • Immunohistochemistry (IHC) – determines the level of protein expression
  • Fluorescent/chromogenic in situ hybridization (FISH/CISH) – determines the division of genes, amplification, translocation and connections
  • Next-generation sequencing (NGS) – studies and determines the somatic mutations using hundreds of ‘hot spots’ of the cancer genome, setting a sequence of the DNA
  • Quantitative polymerase chain reaction (qPCR) – increases and determines the number of target DNA molecules.
  • Immunohistochemistry (IHC) - determines the level of protein expression;

  • Fluorescent / chromogenic in situ hybridization (FISH / CISH) - determines the division of genes, amplification, translocation and connections;

  • Next-generation sequencing (NGS) - more commonly studies and determines the somatic mutations using hundreds of "hot spots" of the cancer genome, setting a sequence of the DNA;

  • Quantitative polymerase chain reaction (qPCR) - increases and determines the number of target DNA molecules.

...

MULTIPLATFORM APPROACH - CARIS EXPERIENCE

Анализ онкомаркеров раковой опухоли

ABOUT TESTING

Tumor Analysis Benefits

Molecular testing enables physicians to select the individual cancer treatment plan that demonstrates the most efficacy for any particular patient..